Merck & Co. Inc.

09/17/2021 | Press release | Distributed by Public on 09/17/2021 05:22

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic[...]